Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WAYNE, PA., MAY 28, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT ON THURSDAY JUNE 4, 2026, AT 2:00 PM ET, ACLARIS' CHIEF EXECUTIVE OFFICER DR. NEAL WALKER AND OTHER MEMBERS OF ACLARIS' SENIOR LEADERSHIP TEAM WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK, NY. A LIVE AND ARCHIVED WEBCAST OF THIS EVENT WILL BE ACCESSIBLE ON THE EVENTS PAGE OF THE ACLARIS WEBSITE, WWW.ACLARISTX.COM.

ACLARIS THERAPEUTICS TO PARTICIPATE IN THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

WAYNE, PA., MAY 08, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT ON THURSDAY MAY 14, 2026, AT 9:35 AM PT, ACLARIS' PRESIDENT AND CHIEF OPERATING OFFICER DR. HUGH DAVIS WILL PROVIDE A CORPORATE PRESENTATION DURING THE 2026 BANK OF AMERICA HEALTHCARE CONFERENCE IN LAS VEGAS, NV. A LIVE AND ARCHIVED WEBCAST OF THIS EVENT WILL BE ACCESSIBLE ON THE EVENTS PAGE OF THE ACLARIS WEBSITE, WWW.ACLARISTX.COM.

ACLARIS THERAPEUTICS TO PARTICIPATE IN THE 2026 BANK OF AMERICA HEALTHCARE CONFERENCE

- FULL TOP LINE RESULTS FROM PHASE 1A SAD/MAD TRIAL OF ATI-052 EXCEED ACLARIS' TARGET PROFILE, VALIDATING POTENTIAL BEST-IN-CLASS POTENCY ADVANTAGE AND OPPORTUNITY FOR EXTENDED DOSING - - UNIQUE DUAL MECHANISM OF ATI-2138 SUPPORTS PLANNED PHASE 2B CLINICAL TRIAL IN LICHEN PLANUS - - STRONG CASH RUNWAY EXPECTED TO ENABLE DEVELOPMENT OF PIPELINE THROUGH 2028 - WAYNE, PA., MAY 07, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDED A CORPORATE AND CLINICAL UPDATE.

ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE AND CLINICAL UPDATE

- POSITIVE FULL RESULTS FROM PHASE 1A TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 EXCEED ACLARIS' TARGET PROFILE, VALIDATING POTENTIAL BEST-IN-CLASS POTENCY ADVANTAGE AND OPPORTUNITY FOR EXTENDED DOSING - - ESTIMATED HALF-LIFE OF APPROXIMATELY 45 DAYS; UNLOCKS OPPORTUNITY FOR UP TO THREE-MONTH DOSING INTERVAL - - COMPLETE AND SUSTAINED INHIBITION OF TSLP-INDUCED AND IL-4 INDUCED CCL17 (TARC) PROVIDES POTENTIAL TO RAISE EFFICACY CEILING IN TH2-DRIVEN DISEASES - - ENROLLMENT AND DOSING ONGOING IN PHASE 1B TRIALS IN ASTHMA AND ATOPIC DERMATITIS (AD) WITH TOP LINE RESULTS EXPECTED IN THE SECOND HALF OF 2026 - - LICHEN PLANUS SELECTED AS LEAD INDICATION FOR ATI-2138; POTENTIAL TO BE FIRST MECHANISTICALLY COMPLETE THERAPEUTIC CANDIDATE DESIGNED TO ADDRESS ROOT INFLAMMATION AND SYMPTOMS - - MANAGEMENT TO HOST A CONFERENCE CALL TO DISCUSS UPDATE TODAY AT 8:30 AM EST - WAYNE, PA., APRIL 28, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY PROVIDED A CLINICAL UPDATE ON ITS BIOLOGIC AND ORAL INHIBITOR COMPOUNDS INCLUDING POSITIVE FULL TOP LINE RESULTS FROM THE FIRST-IN-HUMAN PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ITS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 AND THE SELECTION OF LICHEN PLANUS (LP) AS THE LEAD INDICATION FOR ITS SELECTIVE ITK/JAK3 INHIBITOR ATI-2138.

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE FULL TOP LINE FIRST-IN-HUMAN RESULTS FROM PHASE 1A HEALTHY VOLUNTEER CLINICAL TRIAL OF ATI-052, A NOVEL POTENTIAL FIRST-IN-CLASS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY, AND ANNOUNCES LICHEN PLANUS AS LEAD INDICATION FOR ATI-2138, AN ORAL ITK/JAK3 INHIBITOR

WAYNE, PA., APRIL 27, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT WILL PROVIDE THE FULL RESULTS FROM ITS PHASE 1A SINGLE AND MULTIPLE ASCENDING DOSE TRIAL OF ITS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 AND THE RESULTS OF ITS LEAD INDICATION SELECTION PROCESS FOR ITS ITK/JAK3 INHIBITOR ATI-2138 BEFORE THE OPENING OF THE FINANCIAL MARKETS TOMORROW, APRIL 28, 2026. ACLARIS WILL HOST A WEBCAST AND CONFERENCE CALL WITH SLIDES TOMORROW MORNING AT 8:30 AM EST TO DISCUSS THESE UPDATES.

ACLARIS THERAPEUTICS TO PROVIDE CLINICAL UPDATE ON KEY BIOLOGIC AND ORAL INHIBITOR PROGRAMS ON APRIL 28, 2026

WAYNE, PA., APRIL 08, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT ON TUESDAY, APRIL 14, 2026, AT 12:00 PM EDT, ACLARIS' CHIEF EXECUTIVE OFFICER DR. NEAL WALKER AND OTHER MEMBERS OF ACLARIS' SENIOR LEADERSHIP TEAM WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE H.C. WAINWRIGHT 4TH ANNUAL INFLAMMATORY SKIN DISEASE VIRTUAL CONFERENCE.

ACLARIS THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL INFLAMMATORY SKIN DISEASE VIRTUAL CONFERENCE

- PARTICIPANTS WITH ATOPIC DERMATITIS RECEIVING ATI-2138 EXPERIENCED IMPROVEMENTS IN KEY CLINICAL MEASURES INCLUDING DISEASE SEVERITY, ITCH, AND QUALITY OF LIFE - WAYNE, PA., MARCH 27, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY PROVIDED ADDITIONAL RESULTS FROM ITS PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF ITK AND JANUS KINASE 3 (JAK3), PRESENTED IN AN ELECTRONIC POSTER AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO.

RESULTS PRESENTED AT 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING PROVIDE ADDITIONAL SUPPORT FOR THE THERAPEUTIC POTENTIAL OF ATI-2138

WAYNE, PA., MARCH 20, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT AN EPOSTER ON THE RESULTS FROM ITS OPEN-LABEL PHASE 2A TRIAL OF ATI-2138, A POTENT AND SELECTIVE INVESTIGATIONAL ORAL COVALENT INHIBITOR OF INTERLEUKIN-2-INDUCIBLE T CELL KINASE (ITK) AND JANUS KINASE 3 (JAK3), WILL BE AVAILABLE DURING THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN DENVER, CO. THE POSTER WILL INCLUDE RESULTS NOT PREVIOUSLY REPORTED FROM ACLARIS' PHASE 2A TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS ANNOUNCES POSTER ON RESULTS FROM PHASE 2A TRIAL OF ATI-2138 AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING

- TOP LINE RESULTS EXPECTED IN THE FOURTH QUARTER OF 2026 - WAYNE, PA., MARCH 18, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS COMPLETED PATIENT ENROLLMENT IN ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD).

ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS

- POSITIVE INTERIM RESULTS OF PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 SUPPORT RAPID CLINICAL ADVANCEMENT; COMPLETE TOP LINE RESULTS EXPECTED IN THE SECOND QUARTER OF 2026 -  - PHASE 1B PROOF-OF-CONCEPT TRIALS OF ATI-052 IN ATOPIC DERMATITIS (AD) AND ASTHMA UNDERWAY; TOP LINE RESULTS FROM BOTH TRIALS ANTICIPATED IN THE SECOND HALF OF 2026 -  - INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR LEAD ITK INHIBITOR CANDIDATE ATI-9494 EXPECTED IN THE SECONDHALF OF 2026 -  - ATI-2138, ACLARIS' INVESTIGATIONAL INHIBITOR OF ITK AND JAK3, DEMONSTRATED POTENTIAL BEST-IN-CLASS HAIR REGROWTH IN MURINE ALOPECIA MODEL -  WAYNE, PA., FEB. 26, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED 2025 AND PROVIDED A CORPORATE UPDATE.

Aclaris Therapeutics, Inc.

ACRS

Price

Financial Reports

No items found.

Press Releases

Aclaris Therapeutics, Inc.

ACRS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ACRS